Archive · 13 Aug 2025
Pfizer Launches New Pneumonia Vaccine in India
Imagine tiny germs called Streptococcus pneumoniae that can make you very sick.
Pfizer has a new vaccine in India called PCV20 to fight these germs.
It's like a shield for adults, especially those over 50 or with health problems.
The vaccine helps prevent serious illnesses like lung problems, brain problems, and blood infections.
It's given as one shot and is safer than older vaccines.
Experts say it's a good idea to get vaccinated to avoid getting very sick.
If you are older or have other health issues, talk to your doctor to know if the vaccine is right for you.
Pfizer introduces a new 20-valent pneumococcal conjugate vaccine (PCV20) in India.
The vaccine is designed to protect adults from 20 types of Streptococcus pneumoniae.
PCV20 is approved for adults aged 18 and above, administered as a single dose.
The vaccine aims to prevent severe illnesses like pneumonia and meningitis.
People over 50 and those with certain health issues are at higher risk.
- Who
- Adults aged 18 and above, especially those over 50 or with underlying health issues, can receive the vaccine.
- What
- Pfizer has launched a new 20-valent pneumococcal conjugate vaccine (PCV20) in India.
- When
- The vaccine is newly available in India.
- Where
- India
- Why
- To protect against serious infections caused by Streptococcus pneumoniae bacteria.
- Vaccine Name
- PCV20 (20-valent pneumococcal conjugate vaccine)
- Target
- Adults aged 18 and above
- Administration
- Single dose
- Protects Against
- 20 strains of Streptococcus pneumoniae
- High-Risk Groups
- People over 50, those with asthma, COPD, kidney disease, diabetes, or a weak immune system